title: Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.
abstract: BACKGROUND
  Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal cancer (mCRC). Although specific adverse events have been observed, their risk factors have not been clarified.
  
  
  METHODS
  178 mCRC patients who underwent chemotherapy were retrospectively examined and correlations between possible risk factors and adverse events were analyzed.
  
  
  RESULTS
  87 out of 178 patients were treated with BV-containing chemotherapy. Possible risk factors for BV-related adverse events were: remaining primary tumor, current bleeding, history of arterial thromboembolism (ATE), hypertension, and proteinuria, and these were observed in 22%, 2%, 7%, 16%, and 8% of patients, respectively. Patients with hypertension prior to chemotherapy developed significantly worse hypertension (p=0.018). Gastrointestinal bleeding occurred in 3 out of 18 patients with residual primary tumor (16.7%) and 6 out of 63 patients with no primary tumor (8.7%) (p=0.385).
  
  
  CONCLUSIONS
  Pre-existing hypertension appears to be a risk factor for BV-related deterioration of hypertension.
authors.affiliation: Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 Japan. e-baba@c-oncology.med.kyushu-u.ac.jp.
authors.forename: Taichi
authors.initials: T
authors.lastname: Isobe
authors.forename: Keita
authors.initials: K
authors.lastname: Uchino
authors.forename: Chinatsu
authors.initials: C
authors.lastname: Makiyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ariyama
authors.forename: Shuji
authors.initials: S
authors.lastname: Arita
authors.forename: Shingo
authors.initials: S
authors.lastname: Tamura
authors.forename: Masato
authors.initials: M
authors.lastname: Komoda
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kusaba
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Shirakawa
authors.forename: Taito
authors.initials: T
authors.lastname: Esaki
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsugi
authors.forename: Shigeo
authors.initials: S
authors.lastname: Takaishi
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
authors.forename: Eishi
authors.initials: E
authors.lastname: Baba
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab
keywords: Colorectal cancer; adverse events; bevacizumab; chemotherapy